User contributions for Edzelco
Jump to navigation
Jump to search
11 February 2024
- 00:4200:42, 11 February 2024 diff hist −258 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
- 00:4000:40, 11 February 2024 diff hist +396 User:Edzelco →Peer Reviewed Journal Articles/Abstracts
- 00:3900:39, 11 February 2024 diff hist −207 User:Edzelco →Peer Reviewed Journal Articles/Abstracts (Other than Published)
10 February 2024
- 19:0519:05, 10 February 2024 diff hist +19 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 19:0519:05, 10 February 2024 diff hist +23 Oteseconazole No edit summary current
- 19:0419:04, 10 February 2024 diff hist +25,740 N Oteseconazole Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co..."
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label3.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label2.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA label.png No edit summary current
- 19:0219:02, 10 February 2024 diff hist 0 N File:VIVJOA structure.png No edit summary current
- 18:4718:47, 10 February 2024 diff hist −18 User:Edzelco →Edzel Lorraine Co, DMD, MD
7 February 2024
- 00:4700:47, 7 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +44 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:4700:47, 7 February 2024 diff hist +25,546 N Lutetium (177Lu) vipivotide tetraxetan Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout..." current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto label.png No edit summary current
- 00:4400:44, 7 February 2024 diff hist 0 N File:Pluvicto structure.png No edit summary current
6 February 2024
- 00:5700:57, 6 February 2024 diff hist +35 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:5700:57, 6 February 2024 diff hist +33,106 N Nivolumab and relatlimab-rmbw Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im..." current
- 00:5600:56, 6 February 2024 diff hist 0 N File:Nivolumab and relatlimab-rmbw label.png No edit summary current
- 00:2600:26, 6 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 00:2300:23, 6 February 2024 diff hist −2 Ganaxolone No edit summary current
- 00:2300:23, 6 February 2024 diff hist +24,999 Ganaxolone No edit summary
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle carton.png No edit summary current
- 00:2200:22, 6 February 2024 diff hist 0 N File:Ganaloxone bottle suspension label 50mg.png No edit summary current
- 00:2100:21, 6 February 2024 diff hist 0 N File:Ganaloxone structure.png No edit summary current
2 February 2024
- 15:4915:49, 2 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4915:49, 2 February 2024 diff hist +16 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 15:4815:48, 2 February 2024 diff hist −2 Pacritinib No edit summary current
- 15:4715:47, 2 February 2024 diff hist +29,299 N Pacritinib Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi..."
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Bottle Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib Carton Label.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib supply.png No edit summary current
- 15:4715:47, 2 February 2024 diff hist 0 N File:Pacritinib structure.png No edit summary current
1 February 2024
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5316:53, 1 February 2024 diff hist 0 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +15 User:Edzelco →Pages Authored/Co-authored/Collaborated
- 16:5216:52, 1 February 2024 diff hist +22,285 Mitapivat No edit summary current
- 16:2316:23, 1 February 2024 diff hist −23,245 Mitapivat Blanked the page Tag: Blanking
- 16:2216:22, 1 February 2024 diff hist +1,030 Mitapivat Undo revision 1736932 by Edzelco (talk) Tag: Undo
- 16:2216:22, 1 February 2024 diff hist −1,030 Mitapivat No edit summary
- 16:2116:21, 1 February 2024 diff hist −16 Mitapivat No edit summary
- 16:2016:20, 1 February 2024 diff hist −36 Mitapivat No edit summary
- 16:1916:19, 1 February 2024 diff hist +461 Mitapivat Undo revision 1736928 by Edzelco (talk) Tag: Undo
- 16:1916:19, 1 February 2024 diff hist −461 Mitapivat No edit summary
- 16:1616:16, 1 February 2024 diff hist −4 Mitapivat No edit summary Tag: Manual revert
- 16:1616:16, 1 February 2024 diff hist +4 Mitapivat No edit summary
- 16:1416:14, 1 February 2024 diff hist −2 Mitapivat No edit summary Tag: Manual revert
- 16:1416:14, 1 February 2024 diff hist +2 Mitapivat No edit summary
- 16:1316:13, 1 February 2024 diff hist +23,297 N Mitapivat Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mitapivat |aOrAn=a |drugClass=pyruvate kinase activator |indicationType=treatment |indication=hemolytic anemia in adults with pyruvate kinase (PK) deficiency |adverseReactions=estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia |fdaLIADAdult=PYRUKYND is taken with or without food and swallowed whole. Do not split, crush, chew,..."
- 16:0816:08, 1 February 2024 diff hist 0 N File:Mitapivat 5mg.png No edit summary current
